15-Day Duration of Venetoclax Combined with Azacitidine in Treatment-Naive Higher-Risk Myelodysplastic Syndromes: A Prospective Multicenter Study.

Cancers (Basel) · 2026 · PMC12785011 · PMID 41514667

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significancep = 0.095so close (0.05 < p ≤ 0.1)

showed a trendno p-value reported

Although the difference in OS between the CR group and the non-CR group did not reach statistical significance (log-rank test, p = 0.095), the CR group showed a trend toward prolonged survival (not reached vs. 8.5 months; Figure 2 B).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.